Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by GrahamBon Mar 05, 2021 1:53pm
132 Views
Post# 32729768

RE:RE:RE:JAMA Cardiology Study

RE:RE:RE:JAMA Cardiology Study
G1945V wrote: You say: 

"The question is, is it realistic?

If so, why is there no articles in the cardiology literature, or multi centre clinical trials ongoing , or even just adoption of the technology since it’s approved, given the force of innovation and adoption of digital technologies and other technologies as noted widely and referenced above."



Would you agree that this study may show proof that the VMS 3.0 could be the right diagnostic tool to monitor patients with heart disease especially in children?

 

Ventripoint Heart Analysis System to be used at the Stollery Children's Hospital to Study Atrial Dysfunction in Children


G1945V


This could  be an important study in children of atrial disease, but the topic that I was referring to was the long term implications of  covid on the heart.

 

My understanding, is that children have not had significant problems with COVID related cardiac complication as with adults, however aKawasaki disease-like syndrome has been reported  in children.

There are other standard ways of diagnosing this condition and following it.
 

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370876/ 

And https://www.heart.org/en/news/2020/09/03/what-covid-19-is-doing-to-the-heart-even-after-recovery


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse